Entrada Therapeutics, Inc. (Entrada) is a biopharmaceutical company aiming to transform the lives of patients by establishing a set of medicines, Endosomal Escape Vehicles (EEV) therapeutics, to engage intracellular targets that are considered inaccessible and undruggable. The Company's EEV therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues with an improved therapeutic index. Through its EEV Platform, Entrada is building a development portfolio of oligonucleotide-, antibody- and enzyme-based programs for the potential treatment of neuromuscular diseases, immunology, oncology and diseases of the central nervous system. The Company's lead oligonucleotide programs include ENTR-601-44 targeting Duchenne muscular dystrophy (DMD), and a follow-on program targeting myotonic dystrophy type 1 (DM1). DMD is a monogenic X-linked disease caused by mutations in the DMD gene.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Annual Dividend Rate
Price/Cash Flow (TTM)